About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Texas | 739 Studies

Clinical Trials Ovarian CancerTexas

Ovarian Cancer Clinical Trials in Texas

Find 739 clinical trials for ovarian cancer near Texas. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Texas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 481-500 of 739 trials

CompletedRilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerThis phase II trial studies how well rilotumumab works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer that has failed to respond to…NCT01039207·Burbank, California and 27 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsThe purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in…NCT04895709·Clovis, California and 46 others

Active not recruitingA Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsThe purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.NCT05787587·Phoenix, Arizona and 26 others

CompletedOpen Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid TumorsThis is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with…NCT02307240·San Francisco, California and 3 others

RecruitingMinimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE TrialThis phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are…NCT04575935·Miami, Florida and 18 others

CompletedA Phase 2 Study of Kevetrin in Subjects With Ovarian CancerCellceutix has developed Kevetrin (thioureidobutyronitrile), belonging to an anti-proliferative p53 activator pharmacological class, for the treatment of cancer.NCT03042702·Lebanon, New Hampshire and 1 other

CompletedTLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian CancerThis is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.NCT00052065·Houston, Texas

CompletedCompare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of MalignancyProspective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence…NCT03593681·San Diego, California and 9 others

CompletedCabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal CancerThis phase II trial studies how well cabozantinib-s-malate works in treating patients with ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back or is…NCT02315430·Anchorage, Alaska and 409 others

RecruitingSecondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancerNCT05123807·Houston, Texas

CompletedA Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic CancersThis is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102…NCT05360680·Phoenix, Arizona and 14 others

Active not recruitingTH1902 in Patients With Advanced Solid TumorsOpen label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have…NCT04706962·Detroit, Michigan and 5 others

RecruitingThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or…NCT04585750·Irvine, California and 76 others

TerminatedPhase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsThe purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with fulvestrant in advanced hormone receptor-positive (HR+) solid tumors harboring…NCT05082025·Houston, Texas

TerminatedStudy of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid TumorsThis study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene…NCT04383210·Birmingham, Alabama and 41 others

RecruitingA Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesThe primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab…NCT04300556·Tucson, Arizona and 57 others

CompletedTopotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerRATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.NCT00114166·Hartford, Connecticut and 77 others

TerminatedA Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)Part 1: Dose Escalation.NCT04718675·Birmingham, Alabama and 23 others

Active not recruitingBevacizumab in Ovarian Cancer Patients With Disease at Second-Look SurgeryThe goal of this clinical research study is to learn if Avastin (bevacizumab) can help to control ovarian, fallopian, or primary peritoneal cancer that has been found during…NCT02884648·Houston, Texas

RecruitingStudy of NTB-928 in R/R OCThe goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to…NCT07690189·Birmingham, Alabama and 3 others

PreviousPage 25 of 37Next

Other Conditions in Texas

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia